Shanghai Junshi Biosciences Co (HKSE:01877) Forward Dividend Yield % : 0.00% (As of May. 27, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co Forward Dividend Yield %?

As of today (2024-05-27), the Forward Annual Dividend Yield of Shanghai Junshi Biosciences Co is 0.00%.

As of today (2024-05-27), the Trailing Annual Dividend Yield of Shanghai Junshi Biosciences Co is 0.00%.

HKSE:01877's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.63
* Ranked among companies with meaningful Forward Dividend Yield % only.

Shanghai Junshi Biosciences Co's Dividends per Share for the three months ended in Mar. 2024 was HK$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Shanghai Junshi Biosciences Co's Forward Dividend Yield %

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Junshi Biosciences Co's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's Forward Dividend Yield % falls into.

Shanghai Junshi Biosciences Co Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Shanghai Junshi Biosciences Co (HKSE:01877) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Shanghai Junshi Biosciences Co Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

8SJ:Germany 688180:China

Address

Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN

Website

https://www.junshipharma.com

Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Executives

Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Highbury Investment Pte Ltd	2101 Beneficial owner
Jovial Champion Investments Limited	2201 Interest of corporation controlled by you
Gong Ruilin	2202 Interest of your spouse
Vistra Trust (singapore) Pte. Limited	2201 Interest of corporation controlled by you
Lvc Holdings Limited	2201 Interest of corporation controlled by you
Lvc Management Holdings Limited	2201 Interest of corporation controlled by you
Lvc Innovate Limited	2201 Interest of corporation controlled by you
Lin Lijun	2307 Founder of a discretionary trust who can infl
Lvc Renaissance Fund Lp	2101 Beneficial owner
Lvc Renaissance Limited	2201 Interest of corporation controlled by you
Loyal Valley Innovation Capital (hk) Limited	2201 Interest of corporation controlled by you
Lv Di Kong Gu Ji Tuan Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines